GSK reports positive Phase 3 results for linerixibat in PBC itching

seekingalpha11-20

Wirestock/iStock Editorial via Getty Images GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary biliary cholangitis, or PBC, met...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484205429?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442119524/image_1442119524.jpg","is_english":true,"pubTime":"2024-11-20 00:01","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2484205429","market":"hk","top_or_hot":-1,"title":"GSK reports positive Phase 3 results for linerixibat in PBC itching","media":"seekingalpha","content":"<div>\n<p>Wirestock/iStock Editorial via Getty Images GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary biliary cholangitis, or PBC, met...</p>\n\n<a href=\"https://seekingalpha.com/news/4307531-gsk-reports-positive-phase-3-results-for-linerixibat-in-pbc-itching\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK reports positive Phase 3 results for linerixibat in PBC itching</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK reports positive Phase 3 results for linerixibat in PBC itching\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 00:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4307531-gsk-reports-positive-phase-3-results-for-linerixibat-in-pbc-itching><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wirestock/iStock Editorial via Getty Images GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary biliary cholangitis, or PBC, met...</p>\n\n<a href=\"https://seekingalpha.com/news/4307531-gsk-reports-positive-phase-3-results-for-linerixibat-in-pbc-itching\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK.UK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://seekingalpha.com/news/4307531-gsk-reports-positive-phase-3-results-for-linerixibat-in-pbc-itching","article_id":"2484205429","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442119524/image_1442119524.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484205429","pubTimestamp":1732032117,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Wirestock/iStock Editorial via Getty Images GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary biliary cholangitis, or PBC, met its primary endpoint. The U.K. drugmaker said data showed a significant reduction in baseline in","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK.UK":"葛兰素史克","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc","GSK":"葛兰素史克"},"translate_title":"GSK报告linerixibat治疗PBC瘙痒的3期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":0.9,"GSK.UK":0.6},"content_text":"Wirestock/iStock Editorial via Getty Images GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary biliary cholangitis, or PBC, met its primary endpoint. The U.K. drugmaker said data showed a significant reduction in baseline in","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484205429"}